Ascletis Pharma Inc.
The 01672-HK stock trades on Hong Kong Exchanges And Clearing Ltd
Company Description
Ascletis was established in 2013, and is listed on the Hong Kong Stock Exchange since 2018 (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, NASH/PBC, and cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors) to address unmet medical needs both in China and globally. Gannex, a wholly-owned company of Ascletis,is fully dedicated to the R&D and commercialization of new drugs in the field of NASH.
Drug Pipeline
Source: Ascletis Pharma Inc. - 20220905
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
ASC40
Non-Alcoholic Steatohepatitis
Phase 2
ASC42
Primary Biliary Cholangitis
Phase 2
ASC60
Solid Tumors
Phase 1
ASC63
Advanced Solid Tumours
Preclinical
ritonavir
COVID-19
Reg/Com
0 Comments on 01672-HK stock
Newest
Conversation